Traitement du myélome en Espagne — recevez 3 correspondances personnalisées de cliniques

Spain is a global leader in multiple myeloma care. Modern therapies allow many patients to achieve deep, long-term remission. Spanish hospitals match or exceed the standard of care found in the United States. Traveling abroad is typically only beneficial for highly specific clinical trials.

• Specialized infrastructure: Clinica Universidad de Navarra is JCI-accredited and a recognized European oncology leader.
• Expert volume: Dr. Francesc Cobo Valien at Centro Médico Teknon has 25+ years experience.
• Clinical research: Quironsalud Madrid provides free treatment opportunities through advanced cancer clinical trials.
• Pediatric excellence: SJD Barcelona Children's Hospital is a top 3 European pediatric medical institution.

Bookimed Expert Insight: While patients often consider Germany or the US for oncology, Spain holds the number 3 global rank in our network for patient requests. This popularity stems from centers like Clinica Universidad de Navarra serving 700,000 patients from 70 countries. The concentration of JCI-accredited facilities in Barcelona and Madrid offers a level of safety and expertise that makes international travel unnecessary for standard protocols.

Patient Consensus: Patients note it is better to find a specialist in plasma cell disorders locally than to focus purely on geography. They emphasize that managing costs and care coordination is often easier when staying within the Spanish healthcare system.

Advanced myeloma therapies in Spain include BCMA-targeted CAR T-cell treatments and bispecific antibodies. Patients access these through academic protocols like ARI-0002h at Hospital Clínic de Barcelona or commercial drugs like Cilta-cel. These options are available at JCI-accredited centers in Madrid, Barcelona, and Pamplona.

• Cellular therapy: Academic CAR T-cell options like ARI-0002h provide accessible BCMA-targeted immunotherapy.
• Commercial CAR T: EMA-approved treatments including Cilta-cel and Ide-cel are administered in certified hubs.
• Bispecific antibodies: Off-the-shelf injections like Teclistamab and Talquetamab serve patients needing immediate treatment.
• Specialized centers: Reference hospitals execute complex protocols for patients with triple-class exposed myeloma.

Bookimed Expert Insight: Spain ranks 3rd globally in our network for complex oncology requests. Data shows clinics like Clinica Universidad de Navarra maintain top rankings by combining JCI safety with high-volume research. While major hubs handle most cases, specialized units like the one led by Dr. Francesc Bosch at Quironsalud serve as critical referral points for clinical trials.

Patient Consensus: Patients note that access to CAR T-cell therapy requires failing several standard treatment lines first. They emphasize the importance of early referrals to academic centers because manufacturing wait times and bed availability can vary significantly between regions.

Spanish public hospitals ensure safe myeloma treatment by replacing age-based decisions with objective frailty assessments. Specialists use standardized indexes like the Spanish-developed FI-VIG to categorize patients. This allows medical teams to implement risk-adapted protocols including steroid attenuation and dose-lite drug combinations for frail individuals.

• Frailty stratification: Hospitals utilize the International Myeloma Working Group Index for objective functional screening.
• Dose adjustments: Dexamethasone doses often drop from 40 mg to 10 mg for safety.
• Treatment flexibility: Physicians use sequential dynamic escalation to increase doses only as fitness improves.
• Supportive care: Programs substitute intravenous therapies with subcutaneous injections and home-based symptom management.

Bookimed Expert Insight: Clinical data highlights that Spanish centers like Clinica Universidad de Navarra prioritize personalized drug sequencing over high-intensity protocols. This facility has treated over 700,000 patients and holds multiple Newsweek rankings for oncology. Their approach often includes decentralized care to protect vulnerable patients from hospital-acquired infections during treatment.

Patient Consensus: Patients emphasize that safety relies on frequent bloodwork and rapid dose adjustments rather than rigid adherence to standard schedules. They note that involving family members is vital for tracking early warning signs like infection or neuropathy.

Barcelona, Madrid, and Pamplona are the leading Spanish hubs for myeloma treatment. These cities host Joint Commission International (JCI) accredited facilities specializing in hematology-oncology. Top centers provide autologous stem cell transplants and CAR T-cell therapies. Institutions like Clinica Universidad de Navarra lead in myeloma research and clinical trials.

• Clinica Universidad de Navarra: First JCI-accredited hospital in Spain specializing in aggressive multiple myeloma protocols.
• Centro Médico Teknon: JCI-accredited Barcelona facility offering high-precision diagnostics and specialized adult oncohematology care.
• Quironsalud Madrid: Large tertiary center providing access to experimental blood cancer therapies and trials.
• SJD Barcelona: Global leader in pediatric hematology-oncology for minor patients requiring bone marrow transplants.

Bookimed Expert Insight: Barcelona and Madrid dominate for complex myeloma care due to sheer patient volume and specialization depth. Clinica Universidad de Navarra serves over 700,000 international patients, indicating a massive infrastructure for complex cases. Choosing a larger university hospital like Quironsalud Madrid ensures access to multidisciplinary committees essential for staging refractory disease.

Patient Consensus: Patients note it's important to prioritize speed for the initial workup to avoid treatment delays. Access to dedicated myeloma units and clinical trials often outweighs the convenience of smaller private clinics.

Most myeloma treatments in Spain are administered as outpatient care. You will likely live at home and visit clinics for infusions or pills. Hospitalization is only necessary for intensive procedures like stem cell transplants or if you experience severe side effects or infections.

• Induction phase: Initial therapy typically involves outpatient injections or oral medications at home.
• Stem cell transplant: This phase usually requires a 2-to-3-week inpatient stay for safe monitoring.
• Advanced therapies: CAR T-cell therapy may require 4–9 days of hospitalization for initial dosing.
• Emergency admissions: Stays are reserved for treating severe fevers, kidney issues, or significant pain.

Bookimed Expert Insight: Spain ranks 3rd globally in our database for specialized oncology requests. Leading centers like Centro Médico Teknon or Clinica Universidad de Navarra serve over 140,000 patients annually. Because these centers handle such high volumes, they prioritize efficient outpatient protocols for myeloma. This allows international patients to stay in nearby apartments rather than hospital beds for most of their 6-month treatment cycles.

Patient Consensus: Patients note it is common to feel like a regular at the clinic for labs. They emphasize that while the first cycle feels intense, the schedule becomes a manageable routine once stable.